Back to Agenda
China Town Hall
Session Chair(s)
Ling Su, PhD
Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China
In this forum, speakers from the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) will present and discuss the latest information on regulation, regulatory science, and drug review and approval. Speakers will also discuss recent development in clinical research in China. Attendees will have an opportunity to discuss the issues related to drug regulation with NMPA officials.
Learning Objective : Summarize the latest information on the National Medical Products Administration’s activities in drug regulation; Describe the recent update on the progress in drug review, approval and clinical research in China; Identify challenges in drug development and regulation in China.
Speaker(s)
Opening Remarks and Introductions
Lili Cao, MS
China Center for Food and Drug International Exchange, National Medical Products, China
Deputy Director
Initiatives to Bring More New Drugs to Patients, and Faster
Zhimin Yang, MD
National Medical Products Administration (NMPA), China
Deputy Director, Center for Drug Evaluation
Recent Developments in Regulatory Science and Regulation
Jiangyong Yu
National Medical Products Administration (NMPA), China
Director, Department of Drug Registration
Advancing Clinical Research in China: A Clinical Oncologist’s Perspective
Shun Lu
Shanghai Jiaotong University, China
Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital,
Have an account?